Clevidipine is an intravenous (IV) dihydropyridine calcium-channel blocker (CCB) that is approved for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable. Clevidipine is effective at reducing BP in the emergency room (ER), intensive care unit (ICU), and in the pre-, peri-, and postoperative settings.
New indication: Budesonide/formoterol (Symbicort), a corticosteroid/LABA combination, was approved on February 27, 2009, for the maintenance treatment of COPD
Agents in late-stage development for the treatment of hospital-acquired pneumonia, Clostridium difficile-associated diarrhea, and complicated skin and skin-structure infections.
Changing the work environment to encourage healthy eating and added activity encourages employees
The reinvestment act contains more than $100 billion in federal funding for healthcare initiatives
MedPAC reports 2009 MA payments will be 14% above fee-for-service rates.
New preapproval safety data demands can mean millions of dollars and more years for development
There's a feeding frenzy in Washington as feds dole out the billions in funding from the reinvestment act
The White House is on track to place key thought leaders in pivotal positions to press healthcare reform
Commonwealth Fund State Performance Ranking (2007): 9
More than half of all hospitals use the hospitalist model to deliver inpatient care
The incentives and penalties for adopting EMRs might not help the small physician practices
The shortage of oncologists and the increasing numbers of cancer survivors combine to produce a classic case of demand exceeding supply
A new released by the Cooperative Exchange (CE) sheds new light on claims transactions, revealing just how big a footprint EDI has
Knowing what works will help the country direct its resources toward best buys in healthcare, according to economist Gail Wilensky
Employers use CDHPs to control costs but more focus needs to be on giving members more actionable information.
The number of uninsured hospitalizations increased, according to AHRQ, so the key now is to focus on ways to prevent preventable conditions.
Hospitals using emergency treatment strategies emphasizing evidence-based therapy and better communication among healthcare providers reduced heart attack patient deaths by 19% for up to one year after patient discharge, according to report.
WellPoint decision to sell off its PBM business is seen by experts as good, strategic move for the health insurer.
The CVS privacy settlement sends a clear message to executives that paper privacy and data security are insufficient.
Kansas Gov. Kathleen Sebelius fills HHS secretary post, while Tennessee health commissioner Nancy Ann DeParle fills director of the White House Office for Health Reform.
A retrospective cohort study published in the Journal of the American Medical Association demonstrated that concomitant use of clopidogrel and a proton-pump inhibitor (PPI) after hospital discharge for acute coronary syndrome (ACS) is associated with an increased risk of all-cause mortality and rehospitalization for ACS.
Apparently healthy people with normal cholesterol levels but elevated levels of high-sensitivity C-reactive protein (hsCRP) demonstrated a significant relative reduction in stroke risk if treated with rosuvastatin rather than placebo in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, according to data presented at the International Stroke Conference 2009.
Two-thirds of US hospitals do not administer tissue plasminogen activator (t-PA) to patients who have a stroke and are covered by Medicare, according to the results of a national study conducted between 2005 and 2007, which were presented at the International Stroke Conference 2009.
FDA has issued a public health advisory regarding a risk of burns during magnetic resonance imaging (MRI) scans in patients wearing transdermal medication patches that contain aluminum or other metals in the backing of the patches. The patches can overheat during the scan, leading to skin burns in the area of the patch.
FDA has stated that manufacturers of metoclopramide must add a boxed warning to their drug labels regarding the risk of tardive dyskinesia with long-term or high-dose use of this agent.
Synta Pharmaceuticals and GlaxoSmithKline have announced that they are suspending a phase 3 trial of elesclomol in chemotherapy-naïve patients with stage IV metastatic melanoma because of safety concerns.
At the 2009 annual meeting of the Generic Pharmaceutical Association (GPhA) in February, House Energy and Commerce Committee Chairman Henry Waxman told attendees that a workable scientific, regulatory, and legal pathway for follow-on biologics (also referred to as biogenerics or biosimilar pharmaceuticals) would lead to more affordable medications for Americans.
Catheter delivery of tissue plasminogen activator (t-PA) improves survival and functional outcomes at 6 months in patients with intraventricular hemorrhage (IVH), according to the final results from a phase 2b study known as Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR IVH).
OPKO Health announced that it is terminating a phase 3 trial of bevasiranib for the treatment of wet age-related macular degeneration (wet-AMD).
